Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice

As the COVID-19 pandemic transitions to endemic, seasonal boosters are a plausible reality across the globe. We hypothesize that intranasal vaccines can provide better protection against asymptomatic infections and more transmissible variants of SARS-CoV-2. To formulate a protective intranasal vaccine, we utilized a VLP-based platform. Hepatitis B surface antigen- based virus like particles (VLP) linked with receptor binding domain (RBD) antigen were paired with the TLR4-based agonist adjuvant, BECC 470. K18-hACE2 mice were primed and boosted at four-week intervals with either VLP-RBD-BECC or mRNA-1273. Both VLP-RBD-BECC and mRNA-1273 vaccination resulted in production of RBD-specific IgA antibodies in serum. RBD- specific IgA was also detected in the nasal wash and lung supernatants and were highest in VLP-RBD-BECC vaccinated mice. Interestingly, VLP-RBD-BECC vaccinated mice showed slightly lower levels of pre-challenge IgG responses, decreased RBD-ACE2 binding inhibition, and lower neutralizing activity in vitro than mRNA-1273 vaccinated mice. Both VLP-RBD-BECC and mRNA-1273 vaccinated mice were protected against challenge with a lethal dose of Delta variant SARS-CoV-2. Both vaccines limited viral replication and viral RNA burden in the lungs of mice. CXCL10 is a biomarker of severe SARS-CoV-2 infection and we observed both vaccines limited expression of serum and lung CXCL10. Strikingly, VLP-RBD-BECC when administered intranasally, limited lung inflammation at early timepoints that mRNA-1273 vaccination did not. VLP-RBD-BECC immunization elicited antibodies that do recognize SARS-CoV-2 Omicron variant. However, VLP-RBD-BECC immunized mice were protected from Omicron challenge with low viral burden. Conversely, mRNA-1273 immunized mice had low to no detectable virus in the lungs at day 2. Together, these data suggest that VLP-based vaccines paired with BECC adjuvant can be used to induce protective mucosal and systemic responses against SARS- CoV-2.

[1]  A. Iwasaki,et al.  Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses , 2022, Science.

[2]  Larissa B. Thackray,et al.  Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice , 2022, Nature Medicine.

[3]  T. Randall,et al.  A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts , 2022, Human vaccines & immunotherapeutics.

[4]  M. Esteban,et al.  Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection , 2022, Frontiers in Immunology.

[5]  E. Waltz.  China and India approve nasal COVID vaccines — are they a game changer? , 2022, Nature.

[6]  E. Waltz.  How nasal-spray vaccines could change the pandemic , 2022, Nature.

[7]  A. Gintsburg,et al.  Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates , 2022, Emerging microbes & infections.

[8]  Neil C. Dalvie,et al.  RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge , 2022, mSphere.

[9]  E. Topol,et al.  Operation Nasal Vaccine—Lightning speed to counter COVID-19 , 2022, Science Immunology.

[10]  P. Earl,et al.  Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Ali Zaid,et al.  The Delta SARS-CoV-2 Variant of Concern Induces Distinct Pathogenic Patterns of Respiratory Disease in K18-hACE2 Transgenic Mice Compared to the Ancestral Strain from Wuhan , 2022, mBio.

[12]  B. Mroczko,et al.  What Is Currently Known about the Role of CXCL10 in SARS-CoV-2 Infection? , 2022, International journal of molecular sciences.

[13]  F. H. Damron,et al.  Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge , 2022, npj Vaccines.

[14]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[15]  Neil C. Dalvie,et al.  SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques , 2022, Science advances.

[16]  S. Klein,et al.  A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants , 2022, Journal of extracellular vesicles.

[17]  Wei Chen,et al.  Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial , 2022, Nature Medicine.

[18]  Zhiwei Chen,et al.  Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models , 2022, EBioMedicine.

[19]  Laura E. Crowell,et al.  Scalable, methanol‐free manufacturing of the SARS‐CoV‐2 receptor‐binding domain in engineered Komagataella phaffii , 2021, Biotechnology and bioengineering.

[20]  C. Di Serio,et al.  CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study , 2021, Molecular Medicine.

[21]  W. Greene,et al.  mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status , 2021, eLife.

[22]  K. Stiasny,et al.  Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action , 2021, NPJ vaccines.

[23]  E. Lavelle,et al.  Mucosal vaccines — fortifying the frontiers , 2021, Nature Reviews Immunology.

[24]  D. Meyerholz,et al.  Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5–based COVID-19 vaccine , 2021, Science Advances.

[25]  D. Fremont,et al.  An intranasal vaccine durably protects against SARS-CoV-2 variants in mice , 2021, bioRxiv.

[26]  J. Rini,et al.  Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2 , 2021, bioRxiv.

[27]  A. Sette,et al.  Adaptive immunity to SARS-CoV-2 and COVID-19 , 2021, Cell.

[28]  N. Tchitchek,et al.  Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response , 2020, Frontiers in Immunology.

[29]  A. Pollard,et al.  A guide to vaccinology: from basic principles to new developments , 2020, Nature reviews. Immunology.

[30]  D. Fremont,et al.  A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters , 2020, bioRxiv.

[31]  S. Seo,et al.  Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection , 2020, bioRxiv.

[32]  M. Diamond,et al.  Growth, detection, quantification, and inactivation of SARS-CoV-2 , 2020, Virology.

[33]  R. Wyatt,et al.  Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity. , 2020, Cell reports.

[34]  Neil C. Dalvie,et al.  The yeast stands alone: the future of protein biologic production. , 2018, Current opinion in biotechnology.

[35]  T. Theander,et al.  Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display. , 2017, Vaccine.

[36]  Kelsey A. Gregg,et al.  Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery , 2017, mBio.

[37]  J. Zuckerman.  The importance of injecting vaccines into muscle , 2000, BMJ : British Medical Journal.